<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fresh frozen plasma (FFP), solvent/detergent treated: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fresh frozen plasma (FFP), solvent/detergent treated: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Fresh frozen plasma (FFP), solvent/detergent treated: Drug information</div><div class="clear"></div><div id="topicText">For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16225140"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Octaplas Blood Group A;</li>
<li>Octaplas Blood Group AB;</li>
<li>Octaplas Blood Group B;</li>
<li>Octaplas Blood Group O</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F56993971"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Octaplasma</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F16225142"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Blood Product Derivative</li></ul></div>
<div class="block doa drugH1Div" id="F16225347"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Administer based on ABO-blood compatibility.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bdfd3a7d-73ec-4169-a791-6f6d41d91c35">Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or when undergoing cardiac surgery or liver transplantation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or when undergoing cardiac surgery or liver transplantation:</b> IV: Initial: 10 to 15 mL/kg. <b>Note:</b> Initial dose should increase plasma coagulation factors by ~15% to 25%; if hemostasis is not attained, may use higher doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="afe0d2b3-4ba3-4062-be83-6b990eb17626">Plasma exchange in patients with thrombotic thrombocytopenic purpura</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP):</b> IV: 40 to 60 mL/kg. <b>Note:</b> Dose amount corresponds to 1 to 1.5 plasma volumes. Completely replace plasma volume removed during plasmapheresis with pooled plasma (human).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990357"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987754"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F16225348"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F16225173"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (≥1%), urticaria (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (≥1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (≥1%), paresthesia (≥1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Severe hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort, chest pain, tachycardia, thromboembolism</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema of skin, skin rash</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Alkalosis, hypervolemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased fibrinolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Passive immunization</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Apnea, bronchospasm, dyspnea, pulmonary edema, respiratory failure, tachypnea</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F16225151"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">History of hypersensitivity to pooled plasma (human), fresh frozen plasma (FFP), or to plasma-derived products including any plasma protein; IgA deficiency; severe protein S deficiency.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in the US labeling): IgA deficiency with documented antibodies against IgA.</p></div>
<div class="block war drugH1Div" id="F16225171"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Citrate toxicity: Hypocalcemia and associated symptoms (eg, fatigue, paresthesia, muscle spasm) due to citrate toxicity may occur with infusion rates &gt;1 mL/kg/minute (or 0.02 to 0.025 mmol citrate/kg/minute) especially in patients with hepatic dysfunction. If administering calcium gluconate to minimize citrate toxicity, administer calcium gluconate via another vein.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperfibrinolysis: Because of reduced concentrations of alpha-2 antiplasmin, a physiologic inhibitor of t-PA-induced fibrinolysis, in solvent-detergent treated plasma, an increase in the incidence of hyperfibrinolysis has been observed in patients undergoing liver transplantation; monitor for signs of excessive bleeding (de Jonge 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity (including anaphylactoid or allergic reactions) has been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypervolemia: High infusion rates may induce hypervolemia and subsequent pulmonary edema or heart failure. Monitor patients for signs and symptoms of pulmonary edema or heart failure and begin appropriate therapy if necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombosis: Solvent-detergent treated plasma contains low concentrations of protein S; during therapy, monitor for signs and symptoms of thrombosis in patients at risk. Use is contraindicated in patients with severe protein S deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Transfusion reactions: Administer pooled plasma (human) based on ABO compatibility; transfusion reactions may occur if ABO is mismatched.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may be at increased risk of citrate toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Human plasma: Product of human plasma; may potentially contain infectious agents which could transmit disease, including a theoretical risk of Creutzfeldt-Jakob disease transmission. Infections thought to be transmitted by this product should be reported to the manufacturer or the FDA.</p></div>
<div class="block foc drugH1Div" id="F56355130"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octaplas Blood Group A:  (200 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octaplas Blood Group AB:  (200 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octaplas Blood Group B:  (200 mL)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Octaplas Blood Group O:  (200 mL)</p></div>
<div class="block geq drugH1Div" id="F16225141"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block dinfoc drugH1Div" id="F56993972"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Solution, Intravenous:</p>
<p style="text-indent:-2em;margin-left:4em;">Octaplasma: (200 mL)</p></div>
<div class="block adm drugH1Div" id="F16225351"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">IV: Visually inspect for particulate matter or discoloration prior to administration. Do not use if turbid. Administer IV at a rate ≤1 mL/kg/minute using an infusion set with a filter.</p></div>
<div class="block use drugH1Div" id="F16225146"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">Replacement of multiple coagulation factors in patients with acquired deficiencies due to liver disease or when undergoing cardiac surgery or liver transplantation; plasma exchange in patients with thrombotic thrombocytopenic purpura (TTP)</p></div>
<div class="block mst drugH1Div" id="F16225139"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Octaplas may be confused with Octaplex</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F16265547"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F16265545"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F53128911"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">False positive pregnancy tests may occur following passive transmission of β-human chorionic gonadotropin (Jilma-Stohlawetz 2017).</p>
<p style="text-indent:0em;margin-top:2em;">ADAMTS13 activity should be normalized prior to conception in patients with thrombotic thrombocytopenic purpura who are planning to become pregnant (BSH [Scully 2023]).</p></div>
<div class="block pri drugH1Div" id="F16225148"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Untreated thrombotic thrombocytopenic purpura (TTP) is associated with adverse pregnancy outcomes. Plasma exchange is a recommended option for pregnant patients diagnosed with TTP. ADAMTS13 activity should be monitored at least monthly during pregnancy (BSH [Scully 2023]; ISTH [Zheng 2020]).</p></div>
<div class="block brc drugH1Div" id="F16225150"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">Immunoglobulins, albumin and other components of pooled human plasma are endogenous components of breast milk (IOM 1991). </p></div>
<div class="block mop drugH1Div" id="F16225355"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor response including activated partial thromboplastin time (aPTT), prothrombin time (PT), and/or specific coagulation factors. Monitor for signs of excessive bleeding (patients undergoing liver transplantation); signs and symptoms of pulmonary edema or heart failure; signs and symptoms of thrombosis (in patients at risk).</p></div>
<div class="block pha drugH1Div" id="F16225343"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Replaces human plasma proteins (eg, albumin, immunoglobulin and other globulins, coagulation factors, complement proteins, protease inhibitors)</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11973173">
<a name="11973173"></a>de Jonge J, Groenland TH, Metselaar HJ, et al, “Fibrinolysis During Liver Transplantation is Enhanced by Using Solvent/Detergent Virus-Inactivated Plasma (ESDEP®),” <i>Anesth Analg</i>, 2002, 94(5):1127-31.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/11973173/pubmed" id="11973173" target="_blank">11973173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12695752">
<a name="12695752"></a>Doyle S, O’Brien P, Murphy K, et al, “Coagulation Factor Content of Solvent/Detergent Plasma Compared with Fresh Frozen Plasma,” <i>Blood Coagul Fibrinolysis</i>, 2003, 14(30):283-7.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/12695752/pubmed" id="12695752" target="_blank">12695752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22315257">
<a name="22315257"></a>Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” <i>Chest</i>, 2012, 141(2 Suppl):7-47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/22315257/pubmed" id="22315257" target="_blank">22315257</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine), “Nutrition During Lactation,” National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at <a href="http://www.nap.edu" target="_blank">http://www.nap.edu</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23320451">
<a name="23320451"></a>Jilma-Stohlawetz P, Kursten FW, Horvath M, et al, “Recovery, Safety, and Tolerability of a Solvent/Detergent-Treated and Prion-Safeguarded Transfusion Plasma in a Randomized, Crossover, Clinical Trial In Healthy Volunteers,” <i>Transfusion</i>, 2013 [epub ahead of print].<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/23320451/pubmed" id="23320451" target="_blank">23320451</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28905381">
<a name="28905381"></a>Jilma-Stohlawetz P, Wreford-Bush T, Mills F, et al. False-positive pregnancy test after transfusion of solvent/detergent-treated plasma. <i>Transfusion</i>. 2017;57(12):2965-2968. doi: 10.1111/trf.14304.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/28905381/pubmed" id="28905381" target="_blank">28905381</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Octaplas (pooled plasma [human]) [prescribing information]. Paramus, NJ: Octapharma USA Inc; February 2021.</div>
</li>
<li>
<div class="reference">
                  Octaplasma (pooled plasma [human]) [product monograph]. Toronto, Ontario, Canada: Octapharma Canada Inc; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37586700">
<a name="37586700"></a>Scully M, Rayment R, Clark A, et al; BSH Committee. A British Society for Haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies. <i>Br J Haematol.</i> Published online August 16, 2023. doi:10.1111/bjh.19026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/37586700/pubmed" id="37586700" target="_blank">37586700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32914526">
<a name="32914526"></a>Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. <i>J Thromb Haemost.</i> 2020;18(10):2496-2502. doi:10.1111/jth.15010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/fresh-frozen-plasma-ffp-solvent-detergent-treated-drug-information/abstract-text/32914526/pubmed" id="32914526" target="_blank">32914526</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 88325 Version 61.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
